FGEN
Price
$0.33
Change
-$0.00 (-0.00%)
Updated
May 23 closing price
Capitalization
33.34M
79 days until earnings call
VRCA
Price
$0.61
Change
-$0.03 (-4.69%)
Updated
May 23 closing price
Capitalization
56.58M
80 days until earnings call
Interact to see
Advertisement

FGEN vs VRCA

Header iconFGEN vs VRCA Comparison
Open Charts FGEN vs VRCABanner chart's image
FibroGen
Price$0.33
Change-$0.00 (-0.00%)
Volume$406.37K
Capitalization33.34M
Verrica Pharmaceuticals
Price$0.61
Change-$0.03 (-4.69%)
Volume$112.04K
Capitalization56.58M
FGEN vs VRCA Comparison Chart
Loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. VRCA commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a Buy and VRCA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (FGEN: $0.33 vs. VRCA: $0.61)
Brand notoriety: FGEN and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 45% vs. VRCA: 29%
Market capitalization -- FGEN: $33.34M vs. VRCA: $56.58M
FGEN [@Biotechnology] is valued at $33.34M. VRCA’s [@Biotechnology] market capitalization is $56.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, FGEN is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 4 TA indicator(s) are bullish while VRCA’s TA Score has 5 bullish TA indicator(s).

  • FGEN’s TA Score: 4 bullish, 2 bearish.
  • VRCA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, FGEN is a better buy in the short-term than VRCA.

Price Growth

FGEN (@Biotechnology) experienced а +7.84% price change this week, while VRCA (@Biotechnology) price change was -7.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

FGEN is expected to report earnings on Aug 11, 2025.

VRCA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRCA($56.6M) has a higher market cap than FGEN($33.3M). VRCA YTD gains are higher at: -12.614 vs. FGEN (-37.677). VRCA has higher annual earnings (EBITDA): -65.9M vs. FGEN (-101.15M). FGEN has more cash in the bank: 131M vs. VRCA (46.3M). VRCA has less debt than FGEN: VRCA (45.9M) vs FGEN (79.3M). FGEN has higher revenues than VRCA: FGEN (180M) vs VRCA (7.57M).
FGENVRCAFGEN / VRCA
Capitalization33.3M56.6M59%
EBITDA-101.15M-65.9M153%
Gain YTD-37.677-12.614299%
P/E RatioN/AN/A-
Revenue180M7.57M2,379%
Total Cash131M46.3M283%
Total Debt79.3M45.9M173%
FUNDAMENTALS RATINGS
FGEN vs VRCA: Fundamental Ratings
FGEN
VRCA
OUTLOOK RATING
1..100
116
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6560
P/E GROWTH RATING
1..100
49100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FGEN's Valuation (93) in the Biotechnology industry is in the same range as VRCA (95) in the Pharmaceuticals Major industry. This means that FGEN’s stock grew similarly to VRCA’s over the last 12 months.

FGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that FGEN’s stock grew similarly to VRCA’s over the last 12 months.

FGEN's SMR Rating (100) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that FGEN’s stock grew similarly to VRCA’s over the last 12 months.

VRCA's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as FGEN (65) in the Biotechnology industry. This means that VRCA’s stock grew similarly to FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for VRCA (100) in the Pharmaceuticals Major industry. This means that FGEN’s stock grew somewhat faster than VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENVRCA
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
86%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TBI5.740.08
+1.41%
Trueblue
SE164.060.80
+0.49%
Sea Limited
BRBS3.43-0.02
-0.58%
Blue Ridge Bankshares
CUBI50.75-0.57
-1.11%
Customers Bancorp
ICL6.38-0.08
-1.24%
ICL Group Ltd

FGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, FGEN has been loosely correlated with AVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FGEN jumps, then AVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FGEN
1D Price
Change %
FGEN100%
-0.60%
AVTX - FGEN
57%
Loosely correlated
-1.06%
MGNX - FGEN
45%
Loosely correlated
-4.43%
AXON - FGEN
43%
Loosely correlated
-0.55%
BMRN - FGEN
41%
Loosely correlated
-1.59%
INSM - FGEN
39%
Loosely correlated
+2.29%
More

VRCA and

Correlation & Price change

A.I.dvisor tells us that VRCA and PBYI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VRCA and PBYI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
-4.03%
PBYI - VRCA
32%
Poorly correlated
-0.46%
ACOG - VRCA
30%
Poorly correlated
+5.18%
SLNO - VRCA
29%
Poorly correlated
+4.90%
FGEN - VRCA
29%
Poorly correlated
-0.60%
QURE - VRCA
27%
Poorly correlated
-0.46%
More